These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
188 related articles for article (PubMed ID: 1845094)
21. [Motor complications in patients with Parkinson disease treated with levodopa]. Luquin MR; Obeso JA; Martínez-Lage JM Neurologia; 1989; 4(1):4-11. PubMed ID: 2631806 [TBL] [Abstract][Full Text] [Related]
22. Effect of (-)deprenyl in long-term treatment of Parkinson's disease. A 10-years experience. Birkmayer W; Birkmayer GD J Neural Transm Suppl; 1986; 22():219-25. PubMed ID: 3097256 [TBL] [Abstract][Full Text] [Related]
23. Presynaptic mechanisms of motor fluctuations in Parkinson's disease: a probabilistic model. de la Fuente-Fernández R; Schulzer M; Mak E; Calne DB; Stoessl AJ Brain; 2004 Apr; 127(Pt 4):888-99. PubMed ID: 14960500 [TBL] [Abstract][Full Text] [Related]
24. Controlled-release levodopa/benserazide (Madopar HBS): clinical observations and levodopa and dopamine plasma concentrations in fluctuating parkinsonian patients. Ceballos-Baumann AO; von Kummer R; Eckert W; Weicker H J Neurol; 1990 Feb; 237(1):24-8. PubMed ID: 2181074 [TBL] [Abstract][Full Text] [Related]
26. A study on the effect and tolerance of lisuride on Parkinson's disease. Bayülkem K; Erişir K; Tuncel A; Bayülkem B Adv Neurol; 1996; 69():519-30. PubMed ID: 8615174 [TBL] [Abstract][Full Text] [Related]
28. ["Beginning and end of dose" dyskinesias caused by L-DOPA]. Lhermitte F; Agid Y; Signoret JL; Studler JM Rev Neurol (Paris); 1977 May; 133(5):297-308. PubMed ID: 897439 [TBL] [Abstract][Full Text] [Related]
29. [Benefits of a new galenic form of levodopa and benserazide in the treatment of patients with Parkinson disease]. Dessibourg CA; Gachoud JP Praxis (Bern 1994); 1995 Oct; 84(43):1235-8. PubMed ID: 7481341 [TBL] [Abstract][Full Text] [Related]
30. Concentration-effect relationship of levodopa-benserazide dispersible formulation versus standard form in the treatment of complicated motor response fluctuations in Parkinson's disease. Contin M; Riva R; Martinelli P; Cortelli P; Albani F; Baruzzi A Clin Neuropharmacol; 1999; 22(6):351-5. PubMed ID: 10626097 [TBL] [Abstract][Full Text] [Related]
31. A comparison of Madopar CR and standard Madopar in the treatment of nocturnal and early-morning disability in Parkinson's disease. The U.K. Madopar CR Study Group. Clin Neuropharmacol; 1989 Dec; 12(6):498-505. PubMed ID: 2691069 [TBL] [Abstract][Full Text] [Related]
32. [The L-dopa test in Parkinson's disease]. Esteguy M; Bonnet AM; Kefalos J; Lhermitte F; Agid Y Rev Neurol (Paris); 1985; 141(5):413-5. PubMed ID: 4048732 [TBL] [Abstract][Full Text] [Related]
33. Various aspects of motor fluctuations and their management in Parkinson's disease. Mizuno Y; Kondo T; Mori H Neurology; 1994 Jul; 44(7 Suppl 6):S29-34. PubMed ID: 8047258 [TBL] [Abstract][Full Text] [Related]
34. Efficacy and safety of piribedil in early combination with L-dopa in the treatment of Parkinson's disease: a 6-month open study. Suwantamee J; Nidhinandana S; Srisuwananukorn S; Laptikultham S; Pisarnpong A; Chankrachang S; Bundhukul A J Med Assoc Thai; 2004 Nov; 87(11):1293-300. PubMed ID: 15825702 [TBL] [Abstract][Full Text] [Related]
35. Effectiveness of Madopar HBS plus Madopar standard in patients with fluctuating Parkinson's disease: two years of follow-up. Pacchetti C; Martignoni E; Sibilla L; Bruggi P; Turla M; Nappi G Eur Neurol; 1990; 30(6):319-23. PubMed ID: 2289507 [TBL] [Abstract][Full Text] [Related]
36. Single-dose studies of a slow-release preparation of levodopa and benserazide (Madopar HBS) in Parkinson's disease. Marion MH; Stocchi F; Malcolm SL; Quinn NP; Jenner P; Marsden CD Eur Neurol; 1987; 27 Suppl 1():54-8. PubMed ID: 3322837 [TBL] [Abstract][Full Text] [Related]
37. Treatment of early Parkinson's disease with controlled-release levodopa preparations. Rinne UK; Rinne JO Neurology; 1989 Nov; 39(11 Suppl 2):78-81; discussion 95. PubMed ID: 2586766 [TBL] [Abstract][Full Text] [Related]
38. [Comparative studies of L-DOPA alone and combination with a peripheral DOPA decarboxylase inhibitor, HCL-benserazide, on Parkinson's disease-part I: clinical aspects (author's transl)]. Yokochi M; Kondo T; Hirayama K; Narabayashi H; Kuruma I No To Shinkei; 1979 Mar; 31(3):295-304. PubMed ID: 444336 [No Abstract] [Full Text] [Related]
39. Clinical aspects of motor fluctuations in Parkinson's disease. Poewe WH Neurology; 1994 Jul; 44(7 Suppl 6):S6-9. PubMed ID: 8047260 [TBL] [Abstract][Full Text] [Related]
40. Open multicenter trial with Madopar HBS in parkinsonian patients. Preliminary assessment after short-term treatment. Jansen EN; Meerwaldt JD; Heersema T; van Manen J; Speelman JD Eur Neurol; 1987; 27 Suppl 1():88-92. PubMed ID: 3322841 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]